Developments in Intralesional Therapy for Metastatic Melanoma

Autor: Sarah Sloot, Amod A. Sarnaik, Jonathan S. Zager, Omar M. Rashid
Rok vydání: 2016
Předmět:
Oncology
Pathology
Skin Neoplasms
Electrochemotherapy
medicine.medical_treatment
Phases of clinical research
Herpesvirus 1
Human
Injections
Intralesional
MALIGNANT-MELANOMA
030207 dermatology & venereal diseases
0302 clinical medicine
Medicine
Melanoma
Treatment options
Hematology
General Medicine
Lipids
Oncolytic Viruses
LENTIGO MALIGNA
030220 oncology & carcinogenesis
ROSE-BENGAL
BCG Vaccine
DIRECT GENE-TRANSFER
Immunotherapy
PHASE-II TRIAL
medicine.medical_specialty
Metastatic melanoma
DNA
Recombinant
Locally advanced
Administration
Cutaneous
Article
Genetic therapy
HLA-B7 Antigen
03 medical and health sciences
Internal medicine
BACILLE CALMETTE-GUERIN
Humans
Fluorescent Dyes
Advanced melanoma
Rose Bengal
IN-TRANSIT MELANOMA
business.industry
TOPICAL DIPHENCYPRONE IMMUNOTHERAPY
Granulocyte-Macrophage Colony-Stimulating Factor
Genetic Therapy
DNA-LIPOSOME COMPLEXES
Interleukin-2
business
Zdroj: Cancer causes & control, 23(1), 12-20. SPRINGER
ISSN: 1073-2748
DOI: 10.1177/107327481602300104
Popis: Background Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing. Methods The relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher studies were selected for review. This review also summarizes the mechanisms of action, adverse-event profiles, and clinical data for these agents. Results Intralesional therapies demonstrate promising effects in select patients with advanced melanoma. The optimal approach should be individually tailored and consist of a combination of intralesional therapies, regional perfusions, systemic immunotherapies, targeted therapies, and surgery, if necessary. Conclusions Due to its relatively good local response rates and tolerable adverse-event profile, intralesional therapy may be a treatment option for select patients with unresectable, locally advanced or metastatic melanoma.
Databáze: OpenAIRE
Externí odkaz: